ARS Pharmaceuticals (SPRY) Competitors $17.59 -0.26 (-1.46%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$17.75 +0.16 (+0.90%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY vs. GRFS, TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, PCVX, and CYTKShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Its Competitors Grifols TG Therapeutics Nuvalent Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Grifols (NASDAQ:GRFS) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability. Does the media prefer GRFS or SPRY? In the previous week, Grifols had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Grifols and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.95 beat Grifols' score of 0.56 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, GRFS or SPRY? Grifols has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.85$169.80M$1.178.26ARS Pharmaceuticals$89.15M19.38$8M-$0.16-109.94 Which has more volatility & risk, GRFS or SPRY? Grifols has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Do institutionals & insiders hold more shares of GRFS or SPRY? 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is GRFS or SPRY more profitable? Grifols has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. Grifols' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A ARS Pharmaceuticals -16.11%-6.94%-5.60% Do analysts recommend GRFS or SPRY? Grifols presently has a consensus price target of $10.30, suggesting a potential upside of 6.63%. ARS Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 76.24%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryGrifols and ARS Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.75B$2.43B$5.48B$9.44BDividend YieldN/A1.80%4.01%4.02%P/E Ratio-109.939.0628.3619.90Price / Sales19.38575.80415.0786.48Price / Cash2,107.86165.2635.9658.29Price / Book6.665.068.365.67Net Income$8M$30.99M$3.24B$258.18M7 Day Performance-1.57%2.02%3.13%2.81%1 Month Performance6.16%13.07%10.98%13.53%1 Year Performance70.45%-1.92%34.48%17.68% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals3.0714 of 5 stars$17.59-1.5%$31.00+76.2%+63.6%$1.75B$89.15M-109.9390GRFSGrifols3.318 of 5 stars$9.72-0.2%$10.30+6.0%+22.6%$6.68B$7.81B8.3123,822Upcoming EarningsTGTXTG Therapeutics3.7339 of 5 stars$38.92+5.0%$43.80+12.5%+82.8%$6.18B$329M162.17290Positive NewsNUVLNuvalent3.3354 of 5 stars$84.59+4.5%$119.60+41.4%-0.6%$6.07BN/A-19.2740Analyst ForecastLNTHLantheus4.7007 of 5 stars$83.06+2.2%$131.20+58.0%-36.9%$5.75B$1.53B23.60700Upcoming EarningsRYTMRhythm Pharmaceuticals3.2799 of 5 stars$89.15+2.8%$91.00+2.1%+76.4%$5.67B$130.13M-31.73140AXSMAxsome Therapeutics4.6892 of 5 stars$112.33+3.1%$172.33+53.4%+19.2%$5.53B$385.69M-19.47380TLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/ANews CoverageCRSPCRISPR Therapeutics1.7603 of 5 stars$56.42-0.7%$71.75+27.2%+17.2%$4.87B$37.31M-12.48460Analyst ForecastAnalyst RevisionPCVXVaxcyte1.8628 of 5 stars$36.38+1.3%$136.50+275.2%-57.5%$4.69BN/A-9.12160Positive NewsCYTKCytokinetics4.2443 of 5 stars$38.58+4.2%$70.92+83.8%-34.3%$4.61B$18.47M-7.29250 Related Companies and Tools Related Companies GRFS Competitors TGTX Competitors NUVL Competitors LNTH Competitors RYTM Competitors AXSM Competitors TLX Competitors CRSP Competitors PCVX Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRY) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
